Agenus reports inducement grants under nasdaq listing rule 5635(c)(4)

Lexington, mass.--(business wire)--agenus inc. (“agenus”) (nasdaq: agen), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that the compensation committee of agenus' board of directors granted, as of january 2, 2024 (“grant date”), inducement awards to manuel duenas and benny johnson in connection with their appointments as head of market access and senior medical director, respectively. the compensation committee approved the awards pu.
AGEN Ratings Summary
AGEN Quant Ranking